Waystar Considers Sale Amid Falling Valuation, Hires Evercore

Waystar, a prominent healthcare software company, is contemplating various strategic options including a potential sale, according to sources. This move comes as the company faces a decline in its market valuation, which has fallen to approximately $4.8 billion after a 24% decrease in its share price this year. The company, based in Lehi, Utah, and Louisville, Kentucky, has engaged investment bank Evercore to assist in exploring these options.

Waystar's Strategic Shift

Originally formed from the merger of Zirmed and Navicure in 2017, Waystar has positioned itself as a provider of technology solutions aimed at automating and managing administrative tasks in the healthcare sector. This strategic positioning seeks to capitalize on the higher valuations typically seen in technology companies compared to those in healthcare services, which are more reliant on human labor.

Despite initial investor enthusiasm that pushed Waystar's stock from $20 to a peak of $45 in 2025, the company has since faced pressures. Concerns have mounted over potential disruptions from advancements in artificial intelligence, affecting investor confidence as noted in a Morgan Stanley report from July.

Investment and Ownership

Waystar went public in 2024, backed by major investors including EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital. Currently, EQT holds the largest share with a 13% stake, followed by CPPIB at 10% and BlackRock Institutional Trust Company at 8%, according to data from LSEG.

While EQT and BlackRock have declined to comment on the matter, CPPIB has not yet responded to inquiries. The potential sale process, still in its early stages, could assess whether the appetite for software investments is rebounding amid the broader sector selloff.

Market Conditions and Future Prospects

The potential sale of Waystar emerges as the software sector grapples with significant market fluctuations. The company's decision to hire Evercore signals a proactive approach to navigating these challenges, although sources caution that plans remain tentative and a sale is not guaranteed.

Waystar's exploration of strategic alternatives reflects broader trends in the tech-focused healthcare industry, where companies are seeking to adapt to rapid technological advancements and shifting market dynamics. The outcome of this exploration will likely influence investor sentiment and the strategic direction of similar companies within the sector.